Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback